EBIT: Income before interest and taxes.
Anavex Life Sciences Corp. (AVXL) had EBIT of $-14.46M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-13.24M |
|
-- |
|
-- |
|
$14.46M |
|
$-14.46M |
|
$1.22M |
|
$-13.24M |
|
$-13.24M |
|
$-13.24M |
|
$-13.24M |
|
$-13.24M |
|
$-13.24M |
|
|
EBIT |
$-14.46M |
$-14.46M |
|
85.38M |
|
85.38M |
|
$-0.16 |
|
$-0.16 |
|
| Balance Sheet Financials | |
$102.43M |
|
-- |
|
-- |
|
$102.43M |
|
$11.47M |
|
-- |
|
-- |
|
$11.47M |
|
$90.96M |
|
$90.96M |
|
$90.96M |
|
85.41M |
|
| Cash Flow Statement Financials | |
$-30.44M |
|
-- |
|
$-0.58M |
|
$132.19M |
|
$101.16M |
|
$-31.02M |
|
$7.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-30.44M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.56% |
|
-14.56% |
|
-12.93% |
|
-14.56% |
|
$1.06 |
|
$-0.36 |
|
$-0.36 |
|